Parameter
| Biomarker | [18F]-flortaucipir (tauPET) | Full name | [18F]-flortaucipir (tauPET Imaging) | Molecular Type | Imaging Biomarker |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Pathological Confirmation, Diagnosis |
| Disease | Frontotemporal Dementia | Disease Subtypes | / | ||
| Organ | Brain | Test Sample / Technology Platform | Brain (PET Imaging) | ||
| Pathobiological Mechanisms | Specifically binds to abnormal intracerebral tau aggregation, showing frontotemporal tau deposition in MAPT mutation carriers. | ||||
| Clinical Availability Status | Research validation stage | ||||
| Notes and Dynamics | The positive rate of tauPET in MAPT mutation carriers is 95%; the positive rate in sporadic FTD-tau is 60%, which can predict the rate of cognitive decline. | ||||